Paul Berg—Cahill Professor in Biochemistry, Emeritus, Stanford University; Director, Emeritus, Beckman Center for Molecular and Genetic Medicine at Stanford; Nobel Laureate in Chemistry

Sean Carroll—Investigator, Howard Hughes Medical Institute; Professor of Genetics, University
of Wisconsin, Madison

Frederick Frank—Vice Chairman and Director, Lehman Brothers

Paul Freiman—President and CEO of Neurobiological Technologies; former Chairman and
CEO, Syntex

Martin Gerstel—Chairman of Compugen, Keddem Bioscience, and Evogene; Co-Chairman of Itamar Medical; former Co-Chairman and CEO of ALZA Corporation

Jeff Goldsmith—President, Health Futures

Eric Lander—Director, Broad Institute of MIT and Harvard

Ernest Mario, Ph.D.—Chairman, CEO of Capnia, Palo Alto, California. Capnia is a privately held pharmaceutical company utilizing carbon dioxide as a therapeutic medical gas to treat migraine and rhinitus.

George Poste—CEO, Health Technology Networks; Director, The Biodesign Institute, Arizona
State University; former CSTO and head of R&D, SmithKline Beecham

L. John Wilkerson—Founder of the Wilkerson Group, now an IBM Company and currently
Managing Director of Galen Partners, a late stage healthcare private equity fund

Keith R. Yamamoto—Professor of Cellular and Molecular Pharmacology, Executive Vice Dean
in the School of Medicine at the University of California, San Francisco (UCSF)